Contineum Therapeutics is reporting positive results from its Pipe-791 phase Ib PET trial.
The trial, which included 12 volunteers, met its primary objectives by demonstrating that Pipe-791, Contineum's novel, brain penetrant, small molecule antagonist of the lysophosphatidic acid 1 (LPA1) receptor, achieved high brain receptor occupancy in healthy participants and progressive multiple sclerosis patients. It demonstrated a pharmacokinetic correlation between drug exposure and receptor engagement and showed a safety and tolerability profile consistent with the company’s previous clinical studies.
Contineum added that with these results in mind, planned doses for its future phase II proof-of-concept clinical trials will exceed 90% target coverage with once-daily dosing.
